3PBIOVIAN Animal Health

Animal health innovators increasingly rely on specialized biologics partners to accelerate the development of vaccines, recombinant proteins, monoclonal antibodies, and emerging therapeutic platforms. Expertise in both microbial and mammalian expression systems enables efficient progression from early research through GMP production and commercial supply. Flexible bioreactor capacity, viral‑vector capability, plasmid DNA manufacturing, and multiple modality platforms support a wide range of veterinary programs. Organizations benefit from integrated services that include cell‑line development, process optimization, scale‑up, and robust tech transfer designed to ensure reliability and consistent product quality. With experience spanning startups, established biotechs, global animal‑health companies, and academic institutions, the model emphasizes long‑term partnership, operational agility, and cost‑conscious manufacturing tailored to the needs of the veterinary market. This comprehensive approach helps teams reduce risk, maintain continuity, and bring novel animal therapies to market efficiently while sustaining dependable supply as products advance toward widespread use.